A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.
|Articles|May 1, 2002
Visual vs. computerized analysis of FHR tracings
While most ob/gyns are well-versed in the intricacies of visually interpreting FHR tracings, a growing body of evidence suggests that a software-based approach may yield more clinically useful information.
Advertisement
Advertisement
Related to this article
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA removes boxed warnings from 3 more menopausal hormone therapy products
2
Reactions to FDA's boxed warning removals for menopausal hormone therapy
3
Choosing Among Hormonal and Nonhormonal VMS Therapies in Menopause
4
FDA grants accelerated approval to DNA immunotherapy for adult recurrent respiratory papillomatosis
5